Clinical Trial Finder 2026: How Stage 4 Cancer Patients Can Access Ivermectin, Mebendazole & Repurposed Drug Trials

OneDayMD Editorial Team | Medically reviewed and updated July 2026

Quick Answer Real, registered clinical trials are testing ivermectin and mebendazole in cancer — including a Phase I/II ivermectin + checkpoint-inhibitor trial in metastatic triple-negative breast cancer (NCT05318469) and the ICONIC ivermectin + immunotherapy trial (NCT07487805). Use the searchable tool below, verify current status directly on ClinicalTrials.gov, then contact the study coordinator or ask your oncologist to help you apply. If no trial fits, ask about the expanded access / compassionate use pathway instead of self-sourcing unregulated drugs.

Table of Contents Why Clinical Trials Matter for Stage 4 Patients Interactive Trial Finder Tool Current Ivermectin & Mebendazole Trial Registry (2026) How to Search ClinicalTrials.gov Yourself Understanding Eligibility Criteria Expanded Access & Compassionate Use Red Flags: Real Trials vs. Off-Label Telehealth "Protocols" For Patients in Singapore, Malaysia & Southeast Asia How to Raise This With Your Oncologist Frequently Asked Questions References

1. Why Clinical Trials Matter for Stage 4 Patients

If you've read our coverage of repurposed antiparasitic drugs and the metabolic theory of cancer, you already know the honest, uncomfortable truth: most of the evidence behind ivermectin, mebendazole, and fenbendazole in human cancer is still preclinical or anecdotal. A formal clinical trial is the one pathway that turns "promising in mice" or "one patient's story" into something an oncologist can actually rely on — and it's also, in many cases, the only legal, monitored way to access an investigational combination before it's approved.

Trials matter for three practical reasons beyond the science:

• Monitored safety. You get standardized dosing, lab monitoring, and a research team watching for interactions — instead of self-directed dosing from an online protocol.
• No or reduced cost. Investigational drugs and many trial-related procedures are typically provided at no cost to the participant, which matters enormously for Stage 4 patients weighing options against a limited budget.
• Data that helps the next patient. Every participant contributes to the evidence base ASCO, NCCN, and other bodies will eventually use to decide whether repurposed drugs belong in standard protocols.

2. Interactive Trial Finder Tool

Use the filters below to narrow our curated registry of ivermectin- and mebendazole-related cancer trials, then click through to the live ClinicalTrials.gov listing to check current recruitment status (statuses change often — always verify before contacting a site).

Drug All Drugs Ivermectin Mebendazole Other Repurposed Drug Combination

Status All Statuses Recruiting Active Completed

Search Cancer Type

Trial	Drug(s)	Cancer Type	Phase	Status*	NCT #

No trials match your filters. Try broadening your search or check ClinicalTrials.gov directly using the link below.

*Status shown reflects the last verified check date noted in the registry table below. Trial recruitment status can change weekly — always confirm directly on ClinicalTrials.gov before contacting a site.

Search "ivermectin cancer" live on ClinicalTrials.gov Search "mebendazole cancer" live

3. Current Ivermectin & Mebendazole Trial Registry (2026)

A plain-text summary of the same registry, for readers and AI answer engines that prefer static content:

• NCT07487805 (ICONIC) — Ivermectin combined with an immune checkpoint inhibitor in advanced solid tumors, Phase 1, listed as active with an estimated completion in late 2027 as of the last check.
• NCT05318469 — Ivermectin combined with balstilimab or pembrolizumab, Phase I/II, in metastatic triple-negative breast cancer, listed as recruiting as of the last check.
• NCT02366884 — "Atavistic chemotherapy," combining ivermectin with other repurposed antimicrobials, Phase II, completed.
• NCT03925662 — Mebendazole as an adjuvant treatment in advanced/Stage 4 colon cancer, Phase 2/3, listed as recruiting as of the last check.
• NCT02644291 / related dose-escalation study — Mebendazole plus temozolomide in newly diagnosed adult high-grade glioma, Phase 1, completed; established a maximum studied dose of 200 mg/kg/day with reversible liver enzyme elevation as the main dose-limiting toxicity.
• NCT01837862 — Mebendazole in recurrent pediatric brain tumors, Phase I, completed.
• NCT05402033 — Not a drug trial, but a financial reimbursement and outreach program to help patients afford participation in any therapeutic cancer trial — worth knowing about if cost is a barrier.

4. How to Search ClinicalTrials.gov Yourself

Our registry above is a snapshot — new trials open and close constantly. Here's how to search independently:

1. Go to clinicaltrials.gov and use the search bar with your cancer type plus the drug name (e.g., "pancreatic cancer ivermectin").
2. Filter by Recruitment Status ("Recruiting" or "Not yet recruiting") and by Country if you need a site near you.
3. Open a listing and read the Eligibility Criteria section first — this saves time before you contact anyone.
4. Check the Contacts and Locations section for a study coordinator's phone number or email.
5. Note the Last Verified date — if it's more than a year old, the listed status may be outdated; call to confirm.

5. Understanding Eligibility Criteria

Most repurposed-drug oncology trials share a similar eligibility skeleton, though every trial differs in the details:

• Confirmed diagnosis and stage — usually a specific cancer type and stage (e.g., "metastatic triple-negative breast cancer").
• Prior treatment history — many trials require that standard therapies have already been tried and failed, or that the patient has progressed on the most recent line of treatment.
• Organ function and performance status — adequate liver, kidney, and bone marrow function, and a functional status (often measured by ECOG score) showing the patient can tolerate the study procedures.
• Washout periods — several trials (including the ICONIC ivermectin trial) exclude patients currently taking ivermectin, requiring a washout period first — an important detail for patients who have already self-sourced the drug.
• Contraception requirements — reproductive-age participants are typically required to use contraception during and shortly after the study.

6. Expanded Access & Compassionate Use

If no open trial fits your situation, expanded access (compassionate use) is the formal alternative — a regulated way to request an investigational drug outside a trial. It generally requires:

1. A treating physician willing to submit the request and oversee monitoring.
2. No comparable or satisfactory alternative therapy available.
3. Agreement from the drug's sponsor/manufacturer to provide it.
4. Regulatory sign-off (in the U.S., FDA authorization via a single-patient or intermediate-size expanded access application).

This pathway is case-by-case, not a listed "program" you can browse — your oncologist or a patient advocacy organization affiliated with your cancer type is the right starting point.

Self-reported cancer outcomes at 6-month follow-up (N=122)

7. Red Flags: Real Trials vs. Off-Label Telehealth "Protocols"

Because ivermectin and mebendazole are so widely discussed, it's easy to confuse three very different things. Use this checklist:

Feature	Registered Clinical Trial	Telehealth Off-Label Prescription
Has an NCT number / IRB oversight	Yes	No
Standardized, monitored dosing	Yes	Usually self-directed
Cost to patient	Often free or reimbursed	Out of pocket
Contributes to evidence base	Yes	No structured data collection

Neither column is a moral judgment — some patients reasonably choose off-label routes when no trial is accessible — but knowing which one you're in changes what monitoring and expectations are appropriate.

8. How to Raise This With Your Oncologist

Bring a specific, printed trial listing rather than a general question — it makes the conversation concrete and respects your oncologist's time. Consider a simple script:

"I found this trial, NCT[number], testing [drug] for [my cancer type]. Do you think I'd meet the eligibility criteria, and would you be willing to help me apply or refer me to the study site?"

If your oncologist is unfamiliar with a specific trial, that's normal — there are thousands of active oncology trials at any time. Offer to share the ClinicalTrials.gov link and ask if they can review it or connect you with a clinical trials coordinator at your treatment center.

9. Frequently Asked Questions

Are there real clinical trials testing ivermectin for cancer?

Yes. As of mid-2026, registered trials include a Phase I/II study combining ivermectin with the checkpoint inhibitors balstilimab or pembrolizumab in metastatic triple-negative breast cancer (NCT05318469), and the ICONIC trial studying ivermectin with immune checkpoint inhibition in advanced solid tumors (NCT07487805). Always verify current status directly on ClinicalTrials.gov before contacting a site.

Are there clinical trials testing mebendazole for cancer?

Yes. Mebendazole has been studied in adult high-grade glioma combined with temozolomide, and in pediatric recurrent brain tumors, with additional trials registered in colorectal cancer. Most completed studies so far have been small, early-phase safety and dose-finding trials rather than large randomized efficacy trials.

How do I find out if I'm eligible for a specific clinical trial?

Each ClinicalTrials.gov listing has an Eligibility Criteria section (inclusion and exclusion criteria) and contact information for the study coordinator, who can confirm your eligibility directly. Your oncologist can also help interpret whether you meet criteria.

What is expanded access or compassionate use, and how is it different from a clinical trial?

Expanded access lets a patient outside a formal trial receive an investigational drug when no comparable therapy is available and a physician requests it, with sponsor agreement and regulatory sign-off. It's handled case by case, unlike open trial enrollment.

Is buying ivermectin or mebendazole online the same as joining a clinical trial?

No. Purchasing these drugs through a telehealth platform for off-label use provides no structured monitoring, no tested dosing protocol for cancer, and contributes no data to the evidence base — unlike a registered clinical trial with research oversight.

While You Wait on a Trial: Physician-Guided Support If you're navigating a Stage 4 diagnosis and want a licensed physician consultation to discuss options — including how repurposed-drug research fits into your broader care plan — The Wellness Company offers telehealth access to physicians familiar with this space. Explore The Wellness Company (code ONEDAYMD)

Recommended Reading To understand the science behind why repurposed drugs are being tested in oncology trials at all, Thomas Seyfried's work on the metabolic theory of cancer is a foundational (if contested) starting point. Browse related titles on Amazon →

References

1. ClinicalTrials.gov. Ivermectin in Combination With Balstilimab or Pembrolizumab in Metastatic Triple-Negative Breast Cancer. NCT05318469. clinicaltrials.gov/study/NCT05318469
2. ClinicalTrials.gov. Ivermectin Combined With Immune Checkpoint Inhibition in Cancer (ICONIC). NCT07487805. clinicaltrials.gov/study/NCT07487805
3. ClinicalTrials.gov. Mebendazole as Adjuvant Treatment, Stage 4 Colon Cancer. NCT03925662. clinicaltrials.gov/study/NCT03925662
4. ClinicalTrials.gov. Mebendazole in Recurrent Pediatric Brain Tumors. NCT01837862. clinicaltrials.gov/study/NCT01837862
5. Phase 1 dose-escalation study of mebendazole with temozolomide in newly diagnosed high-grade glioma. PMC7817892.
6. Anticancer Research. Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort. 2026.
7. ClinicalTrials.gov. Cancer Clinical Trials Financial Reimbursement Program. NCT05402033.

Disclaimer: This article is for educational and informational purposes only and does not constitute medical advice. Ivermectin and mebendazole are not FDA-approved cancer treatments; they remain investigational in oncology outside registered clinical trials. Trial recruitment status changes frequently — information here is a snapshot only and must be verified directly on ClinicalTrials.gov. Always consult a qualified oncologist before making any treatment decision, including whether to pursue a clinical trial, expanded access, or off-label therapy.